(Q38103583)

28 August 2017

title

Antibody-based therapy in colorectal cancer (English)

1 reference

28 August 2017

1 reference

2

Gerd Ritter

1 reference

28 August 2017

Takuro Noguchi

1

1 reference

28 August 2017

Hiroyoshi Nishikawa

series ordinal

3

1 reference

28 August 2017

publication date

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

5

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

533-545

1 reference

Adjuvant treatment of colon cancer: what is next?

28 August 2017

cites work

1 reference

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review

21 January 2018

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

Panitumumab: a summary of clinical development in colorectal cancer and future directions

21 January 2018

1 reference

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

21 January 2018

1 reference

The role of bevacizumab in colorectal cancer: understanding its benefits and limitations

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

21 January 2018

1 reference

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

Rituximab: mechanism of action

21 January 2018

1 reference

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma

21 January 2018

1 reference

Fcgamma receptors as regulators of immune responses

21 January 2018

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

21 January 2018

1 reference

Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.

21 January 2018

1 reference

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

21 January 2018

1 reference

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

Antibody therapeutics: isotype and glycoform selection

21 January 2018

1 reference

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

21 January 2018

1 reference

Immune complex-mediated antigen presentation induces tumor immunity

21 January 2018

1 reference

Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells

21 January 2018

1 reference

HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic m

21 January 2018

1 reference

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

21 January 2018

1 reference

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma

21 January 2018

1 reference

The biology of the 17-1A antigen (Ep-CAM)

21 January 2018

1 reference

Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies

21 January 2018

1 reference

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

21 January 2018

1 reference

The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation

21 January 2018

1 reference

Nuclear signalling by tumour-associated antigen EpCAM

21 January 2018

1 reference

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

21 January 2018

1 reference

Adjuvant Therapy with Edrecolomab versus Observation in Stage II Colon Cancer: A Multicenter Randomized Phase III Study*

21 January 2018

1 reference

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581

21 January 2018

1 reference

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

21 January 2018

1 reference

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

21 January 2018

1 reference

Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway

21 January 2018

1 reference

Lewis Y promotes growth and adhesion of ovarian carcinoma-derived RMG-I cells by upregulating growth factors

21 January 2018

1 reference

A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.

21 January 2018

1 reference

Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.

21 January 2018

1 reference

Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium.

21 January 2018

1 reference

The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily

21 January 2018

1 reference

Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer

21 January 2018

1 reference

A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake

21 January 2018

1 reference

(124)I-huA33 antibody PET of colorectal cancer.

21 January 2018

1 reference

NY-ESO-1: review of an immunogenic tumor antigen

21 January 2018

1 reference

Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations

21 January 2018

1 reference

Intracellular tumor-associated antigens represent effective targets for passive immunotherapy.

21 January 2018

1 reference

Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells

21 January 2018

1 reference

Comprehensive molecular characterization of human colon and rectal cancer

21 January 2018

1 reference

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

Expression of tumour-specific antigens underlies cancer immunoediting

21 January 2018

1 reference

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells

21 January 2018

1 reference

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer

21 January 2018

1 reference

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

21 January 2018

1 reference

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

21 January 2018

1 reference

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

21 January 2018

1 reference

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies

21 January 2018

1 reference

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

21 January 2018

1 reference

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.13.35

1 reference

28 August 2017

1 reference